Jafron Biomedical Co.,Ltd.

XSEC:300529 Stock Report

Market Cap: CN¥23.7b

Jafron BiomedicalLtd Valuation

Is 300529 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

3/6

Valuation Score 3/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 300529 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: 300529 (CN¥30.61) is trading above our estimate of fair value (CN¥26.44)

Significantly Below Fair Value: 300529 is trading above our estimate of fair value.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 300529?

Key metric: As 300529 is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for 300529. This is calculated by dividing 300529's market cap by their current earnings.
What is 300529's PE Ratio?
PE Ratio29.5x
EarningsCN¥804.47m
Market CapCN¥23.70b

Price to Earnings Ratio vs Peers

How does 300529's PE Ratio compare to its peers?

The above table shows the PE ratio for 300529 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average36x
300003 Lepu Medical Technology (Beijing)
32.3x42.4%CN¥22.2b
002901 Double Medical Technology
68x44.8%CN¥13.3b
002223 Jiangsu Yuyue Medical Equipment & Supply
20.7x18.7%CN¥35.7b
300482 Guangzhou Wondfo BiotechLtd
23x27.5%CN¥11.8b
300529 Jafron BiomedicalLtd
29.5x26.1%CN¥23.7b

Price-To-Earnings vs Peers: 300529 is good value based on its Price-To-Earnings Ratio (29.5x) compared to the peer average (35.2x).

Price to Earnings Ratio vs Industry

How does 300529's PE Ratio compare vs other companies in the CN Medical Equipment Industry?

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
No more companies available in this PE range
300529 29.5xIndustry Avg. 35.5xNo. of Companies16PE020406080100+
0 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: 300529 is good value based on its Price-To-Earnings Ratio (29.5x) compared to the CN Medical Equipment industry average (35.2x).

Price to Earnings Ratio vs Fair Ratio

What is 300529's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

300529 PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio29.5x
Fair PE Ratio32.9x

Price-To-Earnings vs Fair Ratio: 300529 is good value based on its Price-To-Earnings Ratio (29.5x) compared to the estimated Fair Price-To-Earnings Ratio (32.9x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst 300529 forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentCN¥30.61
CN¥38.21
+24.8%
11.0%CN¥42.41CN¥34.00n/a2
Nov ’25CN¥30.48
CN¥38.21
+25.3%
11.0%CN¥42.41CN¥34.00n/a2
Oct ’25CN¥32.74
CN¥33.95
+3.7%
0.2%CN¥34.00CN¥33.89n/a2
Sep ’25CN¥25.08
CN¥33.95
+35.3%
0.2%CN¥34.00CN¥33.89n/a2
Aug ’25CN¥26.53
CN¥33.95
+27.9%
0.2%CN¥34.00CN¥33.89n/a2
Jul ’25CN¥27.99
CN¥33.95
+21.3%
0.2%CN¥34.00CN¥33.89n/a2
Jun ’25CN¥27.58
CN¥33.95
+23.1%
0.2%CN¥34.00CN¥33.89n/a2
May ’25CN¥27.54
CN¥30.95
+12.4%
9.5%CN¥33.89CN¥28.00n/a2
Apr ’25CN¥23.00
CN¥26.62
+15.7%
5.2%CN¥28.00CN¥25.23n/a2
Mar ’25CN¥20.66
CN¥26.62
+28.8%
5.2%CN¥28.00CN¥25.23n/a2
Feb ’25CN¥17.70
CN¥26.62
+50.4%
5.2%CN¥28.00CN¥25.23n/a2
Jan ’25CN¥22.23
CN¥26.62
+19.7%
5.2%CN¥28.00CN¥25.23n/a2
Dec ’24CN¥24.16
CN¥26.62
+10.2%
5.2%CN¥28.00CN¥25.23n/a2
Nov ’24CN¥23.22
CN¥32.62
+40.5%
22.6%CN¥40.00CN¥25.23CN¥30.482
Oct ’24CN¥22.51
CN¥38.52
+71.1%
3.8%CN¥40.00CN¥37.04CN¥32.742
Sep ’24CN¥20.75
CN¥38.52
+85.6%
3.8%CN¥40.00CN¥37.04CN¥25.082
Aug ’24CN¥23.64
CN¥38.52
+62.9%
3.8%CN¥40.00CN¥37.04CN¥26.532
Jul ’24CN¥23.18
CN¥38.52
+66.2%
3.8%CN¥40.00CN¥37.04CN¥27.992
Jun ’24CN¥26.65
CN¥38.52
+44.5%
3.8%CN¥40.00CN¥37.04CN¥27.582

Analyst Forecast: Target price is more than 20% higher than the current share price, but there are not enough analysts covering the stock to determine statistical confidence in agreement.

Discover undervalued companies

Shenzhen Lifotronic Technology

CN¥7.0b

Research, develops, manufactures, and markets medical devices for diagnostics, clinical medicine, skin, and human health related purposes in China.

688389

CN¥16.65

7D

-4.6%

1Y

-27.1%

Winner Medical

CN¥19.4b

Engages in the research and development, manufacture, and marketing of cotton-based medical dressings and medical disposables, and consumer products in China.

300888

CN¥33.40

7D

0.4%

1Y

-16.2%

Innovita Biological Technology

CN¥5.6b

Engages in the research and development, manufacturing, marketing, and sales of POCT rapid diagnostic products.

688253

CN¥40.80

7D

-8.7%

1Y

59.1%